Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies

Research output: Contribution to journalArticlepeer-review

Abstract

The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.

Original languageEnglish (US)
Article numbere23660
JournalOncoImmunology
Volume2
Issue number4
DOIs
StatePublished - Apr 2013

Keywords

  • Anti-PD1
  • Cancer immunotherapy
  • Immune checkpoint blockade
  • Nivolumab
  • Re-induction

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies'. Together they form a unique fingerprint.

Cite this